Literature DB >> 8843419

The rat osteocalcin fibroblast growth factor (FGF)-responsive element: an okadaic acid-sensitive, FGF-selective transcriptional response motif.

E P Newberry1, J M Boudreaux, D A Towler.   

Abstract

We recently identified a bipartite element in the rat osteocalcin (OC) promoter that confers synergistic induction by fibroblast growth factor receptor 2 (FGF2) and cAMP. A GCAGTCA motif (OCFRE) at -146 to -138 in the OC promoter is necessary for synergy and participates in a FGF2-regulated DNA-protein interaction. We have isolated the FGF-regulated component of this transcriptional response for detailed study. Two or three copies of the OC promoter fragment -154 to -113 with the intact OCFRE confer 10- or 30-fold FGF2-inductive responses, respectively, on the unresponsive basal promoter 92 OCLUC (luciferase reporter) in MC3T3-E1 cells; a single copy is insufficient. As in the native context, induction depends upon an intact OCFRE motif (mutant GCATTTA motifs unresponsive). FGF receptor 1 can mediate activation; expression of this receptor in L6 cells (no endogenous FGF receptors) permits FGF2 induction of (OCFRE)2 92 OCLUC. FGF2 induction of (OCFRE)2 92 OCLUC in MC3T3-E1 cells is not recapitulated by platelet-derived growth factor-BB, epidermal growth factor, insulin-like growth factor I, or transforming growth factor-beta (< 10% the activity of FGF2). OCFRE activation is not inhibited by kinase inhibitors H-89, wortmannin, staurosporine, KN-62, or H-7. However, the phosphoprotein phosphatase inhibitors okadaic acid (OKA), calyculin A, and vanadate decrease FGF induction of (OCFRE)2 92 OCLUC or (OCFRE)3 92 OCLUC, without inhibiting induction of the interstitial collagenase promoter. OKA and calyculin A do not decrease OCFRE DNA-protein interactions, suggesting that important protein-protein interactions are phosphatase regulated. These data provide evidence that; 1) FGF receptors elaborate transcriptional activation signals that functionally differ from those of other receptor tyrosine kinases; 2) an OKA-sensitive phosphatase participates in FGF receptor-dependent activation of the OCFRE; and 3) two transcriptional activation signals are initiated by FGF receptor activation in MC3T3-E1 cells, reflected in the divergent sensitivities of OCFRE and interstitial collagenase promoter induction to OKA and vanadate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843419     DOI: 10.1210/mend.10.8.8843419

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  11 in total

1.  Runx2 trans-activation mediated by the MSX2-interacting nuclear target requires homeodomain interacting protein kinase-3.

Authors:  Oscar L Sierra; Dwight A Towler
Journal:  Mol Endocrinol       Date:  2010-05-19

2.  TNFR1-activated reactive oxidative species signals up-regulate osteogenic Msx2 programs in aortic myofibroblasts.

Authors:  Chung-Fang Lai; Jian-Su Shao; Abraham Behrmann; Karen Krchma; Su-Li Cheng; Dwight A Towler
Journal:  Endocrinology       Date:  2012-06-08       Impact factor: 4.736

3.  Extracellular matrix protein anosmin promotes neural crest formation and regulates FGF, BMP, and WNT activities.

Authors:  Yukinori Endo; Hiroko Ishiwata-Endo; Kenneth M Yamada
Journal:  Dev Cell       Date:  2012-08-14       Impact factor: 12.270

4.  Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome.

Authors:  K Yu; A B Herr; G Waksman; D M Ornitz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

5.  Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome.

Authors:  A Lomri; J Lemonnier; M Hott; N de Parseval; E Lajeunie; A Munnich; D Renier; P J Marie
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

6.  Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism.

Authors:  Nelly Pitteloud; Richard Quinton; Simon Pearce; Taneli Raivio; James Acierno; Andrew Dwyer; Lacey Plummer; Virginia Hughes; Stephanie Seminara; Yu-Zhu Cheng; Wei-Ping Li; Gavin Maccoll; Anna V Eliseenkova; Shaun K Olsen; Omar A Ibrahimi; Frances J Hayes; Paul Boepple; Janet E Hall; Pierre Bouloux; Moosa Mohammadi; William Crowley
Journal:  J Clin Invest       Date:  2007-01-18       Impact factor: 14.808

7.  Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation.

Authors:  Kenneth E White; Jose M Cabral; Siobhan I Davis; Tonya Fishburn; Wayne E Evans; Shoji Ichikawa; Joanna Fields; Xijie Yu; Nick J Shaw; Neil J McLellan; Carole McKeown; David Fitzpatrick; Kai Yu; David M Ornitz; Michael J Econs
Journal:  Am J Hum Genet       Date:  2004-12-28       Impact factor: 11.025

8.  Impaired fibroblast growth factor receptor 1 signaling as a cause of normosmic idiopathic hypogonadotropic hypogonadism.

Authors:  Taneli Raivio; Yisrael Sidis; Lacey Plummer; Huaibin Chen; Jinghong Ma; Abir Mukherjee; Elka Jacobson-Dickman; Richard Quinton; Guy Van Vliet; Helene Lavoie; Virginia A Hughes; Andrew Dwyer; Frances J Hayes; Shuyun Xu; Susan Sparks; Ursula B Kaiser; Moosa Mohammadi; Nelly Pitteloud
Journal:  J Clin Endocrinol Metab       Date:  2009-10-09       Impact factor: 5.958

9.  Connexin43 potentiates osteoblast responsiveness to fibroblast growth factor 2 via a protein kinase C-delta/Runx2-dependent mechanism.

Authors:  Florence Lima; Corinne Niger; Carla Hebert; Joseph P Stains
Journal:  Mol Biol Cell       Date:  2009-04-01       Impact factor: 4.138

10.  Incidence, phenotypic features and molecular genetics of Kallmann syndrome in Finland.

Authors:  Eeva-Maria Laitinen; Kirsi Vaaralahti; Johanna Tommiska; Elina Eklund; Mari Tervaniemi; Leena Valanne; Taneli Raivio
Journal:  Orphanet J Rare Dis       Date:  2011-06-17       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.